Immatics (IMTX) Change in Accured Expenses (2019 - 2024)
Immatics (IMTX) reported Change in Accured Expenses of -$34.4 million for Q1 2024, down 311.37% on a YoY basis from $16.3 million in Q2 2023, and down 303.35% sequentially from $16.9 million in Q4 2023.
Immatics (IMTX) Change in Accured Expenses (2019 - 2024) Analysis & Trends
Immatics (IMTX) has 6 years of Change in Accured Expenses data on file, last reported at -$34.4 million in Q1 2024.
- For the quarter ending Q1 2024, Change in Accured Expenses fell 311.37% year-over-year to -$34.4 million; the trailing twelve-month figure through Mar 2024 stood at -$26.0 million (down 433.43% YoY), and the FY2025 full-year result was -$42.5 million, up 73.78% from the prior year.
- Change in Accured Expenses fell to -$34.4 million in Q1 2024, from $16.9 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $68.4 million in Q2 2022 to a low of -$39.4 million in Q4 2022.
- A 5-year average of -$2.7 million and a median of -$6.3 million in 2023 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses surged 1304.44% in 2022 and plunged 311.37% in 2024, its largest moves.
- Tracing IMTX's Change in Accured Expenses over 5 years: stood at -$11.0 million in 2020, then tumbled by 82.9% to -$20.1 million in 2021, then sank by 96.28% to -$39.4 million in 2022, then surged by 142.94% to $16.9 million in 2023, then tumbled by 303.35% to -$34.4 million in 2024.
- Business Quant data shows IMTX's Change in Accured Expenses at -$34.4 million in Q1 2024, $16.9 million in Q4 2023, and -$6.3 million in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -16.74 Mn |
| 10 | Immatics | 1.06 Bn | 515.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -34.41 Mn |
| Mar 31, 2024 | -34.41 Mn |
| Dec 31, 2023 | 16.92 Mn |
| Dec 31, 2023 | 16.92 Mn |
| Sep 30, 2023 | -6.26 Mn |
| Sep 30, 2023 | -6.26 Mn |
| Jun 30, 2023 | -2.28 Mn |
| Jun 30, 2023 | -2.28 Mn |
| Mar 31, 2023 | -8.36 Mn |
| Mar 31, 2023 | -8.36 Mn |
| Dec 31, 2022 | -39.41 Mn |
| Dec 31, 2022 | -39.41 Mn |
| Sep 30, 2022 | -12.85 Mn |
| Sep 30, 2022 | -12.85 Mn |
| Jun 30, 2022 | 68.43 Mn |
| Jun 30, 2022 | 68.43 Mn |
| Mar 31, 2022 | 36.81 Mn |
| Mar 31, 2022 | 36.81 Mn |
| Dec 31, 2021 | -20.08 Mn |
| Dec 31, 2021 | -20.08 Mn |